ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 980

Annual Medical Care Expenditures Among US Adults with Osteoarthritis, 2008 – 2011

Miriam G. Cisternas1, Louise Murphy2, David J. Pasta3, Daniel H. Solomon4 and Charles G. Helmick5, 1MGC Data Services, Carlsbad, CA, 2Division of Population Health, Centers for Disease Control and Prevention, Atlanta, GA, 3DMA Corporation, Palo Alto, CA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: OA

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoarthritis

Session Type: Abstract Submissions (ARHP)

Background/Purpose: As the US population ages, concerns continue to grow about the cost of medical treatment for osteoarthritis (OA). We estimated all-cause medical care expenditures and OA-attributable expenditures among US adults with OA age ≥ 18 years.  

Methods: We identified adults with OA in the 2008-2011 Medical Expenditure Panel Survey (MEPS). Adults were defined as having OA if (1) ICD-9-CM 715 was present, or (2) ICD-9-CM 716 or 719 was present along with self-reported doctor-diagnosed arthritis that excluded rheumatoid arthritis. We estimated annual national total (aggregate) and mean per-person all-cause and OA-attributable expenditures overall and for four expenditure categories: ambulatory care (office-based and hospital outpatient); inpatient care; prescriptions; and other (emergency room visits, home health care, vision aids, dental visits, and medical devices). OA-attributable expenditures were calculated using multi-stage regression models that adjusted for demographics (age, sex, race, Hispanic ethnicity, and education), health insurance coverage (any private, public only, or none), and 9 costly comorbid conditions. The increment was our estimate of expenditures that would be expected if those with OA did not have the condition by applying the parameter estimates from the models of those without OA to the data from those with OA.  Estimates are in 2011 US dollars.

Results: National total all-cause medical care expenditures among the 30.8 million adults reporting OA were $328.2 billion; mean per-person expenditures among US adults with OA were $10,654, compared to $4,884 for all adults.  Across expenditure categories, all-cause mean per-person expenditures were: ambulatory care ($3,354), inpatient ($3,320), prescriptions ($2,546), and other ($1,434).  National OA-attributable expenditures totaled $62.1 billion (mean per person=$2,017) and accounted for 6% ($62.1 billion/$1,122.0 billion) of all medical expenditures for US adults.  Mean per-person OA-attributable expenditures followed the same order as all-cause expenditures: ambulatory care ($754), inpatient ($544), prescriptions ($348), and other ($185).

Conclusion: Mean per-person all-cause medical expenditures were more than double for adults with OA compared to the entire adult population. Total annual national medical expenditures attributable to OA were $62.1 billion, accounting for 6% of medical expenditures for US adults.  The increasing prevalence of obesity and continued aging of the population suggest that medical expenditures for treating OA will increase in the future. Underused interventions such as weight management, physical activity, and self-management education may mitigate its adverse effects on symptoms and function.


Disclosure:

M. G. Cisternas,
None;

L. Murphy,
None;

D. J. Pasta,
None;

D. H. Solomon,

Pfizer Inc,

2,

Amgen,

2,

Lilly,

2,

Corrona,

2,

UpToDate,

7;

C. G. Helmick,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/annual-medical-care-expenditures-among-us-adults-with-osteoarthritis-2008-2011/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology